AOD-9604 vs Semaglutide: The Honest Comparison

The Short Answer

If the question is which of these produces meaningful weight loss, the comparison is over quickly. Semaglutide belongs to the GLP-1 receptor agonist class, the drugs that changed obesity medicine over the past decade. AOD-9604 is a growth hormone fragment that was built to be an obesity drug, got its shot at proving it in a proper Phase 2b trial, and missed. Its developer shut the obesity program down in 2007. Those two sentences settle the weight loss question, and any comparison page that does not put them near the top is selling you something.

The reason this page exists anyway is that the searches keep coming, and the people making them are usually running a specific calculation: AOD-9604 costs about $20 less per month than compounded semaglutide, has a reputation for being gentle, and gets marketed as a fat-loss peptide without the GLP-1 side effects. Parts of that are true. The safety reputation, in particular, is earned. What the marketing leaves out is the efficacy record, which is the one thing that should drive this decision.

So this guide does the comparison honestly. The failed trial first, in plain terms, including what the trials actually did show and the genuine open question the oral dosing left behind. Then the mechanisms, the price math, who might still reasonably be interested in AOD-9604, and who should be having the GLP-1 conversation instead. If you want the same framing applied to a different growth hormone peptide, the sermorelin vs semaglutide comparison Read nextSermorelin vs Semaglutide: Different JobsThese two get compared constantly, usually by people trying to sell one of them. They are not competitors. A GLP-1 receptor agonist changes how hungry you are. Sermorelin nudges your pituitary to release more of your own growth hormone. Only one of them is a weight loss medication, and it is not sermorelin.Read article is this page’s sibling.

What Happened in 2007

The idea behind AOD-9604 was genuinely elegant. Growth hormone is one of the body’s most potent fat-mobilizing signals, but full-length GH also raises IGF-1, disrupts blood sugar, and drives tissue growth, which makes it a poor weight loss drug. In 1993, Frank Ng’s biochemistry lab at Monash University in Melbourne showed that the fat-metabolism function lives in a tiny stretch near the tail of the molecule: amino acids 177 through 191. That fragment, less than a tenth of the full hormone, reproduced its complete antilipogenic activity in fat cells while leaving out everything else. Add a stabilizing tyrosine to the front end and you have AOD-9604.

Wu Z, Ng FM, "Antilipogenic action of synthetic C-terminal sequence 177-191 of human growth hormone," Biochemistry and Molecular Biology International, 1993;30(3):547-555. View study

Metabolic Pharmaceuticals, an Australian biotech, licensed the peptide and took it into formal clinical development for obesity, a program tracked in the pharmaceutical pipeline literature of the time. The early results looked like a drug being born. In the 2004 Phase 2a trial, about 300 patients took oral AOD-9604 for 12 weeks, and the 1 mg dose group lost an average of 2.8 kg against 0.8 kg on placebo. Small numbers by GLP-1 standards, but statistically real, and enough to justify the bigger study.

Wilding J, "AOD-9604 Metabolic," Current Opinion in Investigational Drugs, 2004;5(4):436-440. View study

The bigger study is where it ended. The Phase 2b OPTIONS trial enrolled 536 patients and ran oral doses of 0.25, 0.5, and 1 mg daily for 24 weeks, and it did not reach statistical significance on its primary weight loss endpoint. The promising Phase 2a signal did not replicate at scale. Metabolic Pharmaceuticals discontinued the obesity program in 2007, and no company has taken AOD-9604 back into an efficacy trial since. Worth knowing: the detailed trial results were reported by the company and never published in a PubMed-indexed journal, so the numbers above come from the development program’s public record rather than from peer-reviewed papers.

Now the other half, because a failed efficacy trial is not the same thing as a dangerous drug. Across six randomized, double-blind, placebo-controlled trials enrolling roughly 893 subjects, AOD-9604 was well tolerated. No serious adverse events were attributed to the peptide, side effects ran at placebo-like rates, and repeated testing confirmed no changes in IGF-1, insulin sensitivity, or blood glucose. That clean record is what later supported the FDA granting GRAS status for oral AOD-9604 in 2013, a food-safety designation rather than a drug approval. Nearly 900 humans is more safety data than almost any other peptide in the compounding space can point to. It is efficacy data the program lacks, not safety data.

Two Mechanisms, Nothing in Common

AOD-9604: the lipolysis fragment

AOD-9604 acts directly on fat tissue. It stimulates lipolysis, the breakdown of stored triglycerides into fatty acids the body can burn, and inhibits lipogenesis, the creation of new fat. The mechanistic anchor is a 2001 Endocrinology study from the Monash group: in obese mice with normal beta-3 adrenergic receptors, AOD-9604 reduced weight and increased fat oxidation, while in knockout mice lacking those receptors it did nothing at all. The beta-3 pathway is the switch it flips.

Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM, "The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice," Endocrinology, 2001;142(12):5182-5189. View study

What it deliberately does not do defines its appeal. Because the fragment lacks the regions of growth hormone that signal growth and disrupt glucose handling, it does not raise IGF-1, does not impair insulin sensitivity, and does not touch blood sugar. It also does not suppress appetite, which matters for this comparison: AOD-9604 never reduces how much you eat. It nudges what fat cells do with what is already stored. The full mechanism story, including the parallel mouse work on fat oxidation, is in the AOD-9604 guide Read nextAOD-9604: The Fat-Burning Fragment That Came From Growth HormoneGrowth hormone burns fat. It also raises blood sugar, swells joints, and can trigger abnormal growth. In 1993, an Australian biochemist isolated the 16 amino acids responsible for fat metabolism and nothing else. That fragment became AOD-9604.Read article .

Heffernan MA, Thorburn AW, Fam B, Summers R, Conway-Campbell B, Waters MJ, Ng FM, "Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment," International Journal of Obesity and Related Metabolic Disorders, 2001;25(10):1442-1449. View study

Semaglutide: appetite and gastric emptying

Semaglutide works upstream of fat cells entirely. It mimics GLP-1, a hormone the small intestine releases after eating, engineered to resist the enzyme that clears natural GLP-1 within minutes so it can be dosed once weekly. It acts on receptors in the hypothalamus and brainstem that govern fullness, slows gastric emptying so meals satisfy longer, and enhances insulin release only when glucose is elevated. Drucker’s 2018 review in Cell Metabolism remains the clearest account of the receptor biology.

Drucker DJ, "Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1," Cell Metabolism, 2018;27(4):740-756. View study

The practical result is that people eat substantially less without white-knuckling it, and the gastric effect is directly measurable: in a pharmacology study in adults with obesity, semaglutide delayed first-hour gastric emptying after a meal. That is the engine of the weight loss. A GLP-1 creates a caloric deficit pharmacologically, and in trials of the approved branded products, that deficit compounded into double-digit percentage reductions in body weight. AOD-9604’s best trial result, the one that did not survive replication, was 2.8 kg. These are not two sizes of the same effect. They are different orders of magnitude.

Hjerpsted JB, Flint A, Brooks A, Axelsen MB, Kvist T, Blundell J, "Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity," Diabetes, Obesity and Metabolism, 2018;20(3):610-619. View study

Head to Head

The $20 Question

Here is the math people actually run before landing on this page. AOD-9604 is $229 a month when in stock. Compounded semaglutide is $249 a month as a subscription, one vial per 28 days. Twenty dollars separates them, and if the two products did the same job, the cheaper one would be the rational pick.

They do not do the same job, so the $20 frame is the wrong one. Spent on AOD-9604, $229 buys a well-tolerated lipolysis signal whose best human result was 2.8 kg over 12 weeks in a trial that a larger study then failed to confirm. Spent on semaglutide, $249 buys a weekly injection from the drug class with the strongest weight loss evidence in medicine. Per kilogram of expected result, the cheaper product is by far the more expensive one. If budget is the deciding factor, the answer is not to buy the weaker peptide; it is to have the GLP-1 conversation and decide whether semaglutide at $249 or tirzepatide at $399 fits it. How PeRx thinks about that decision, including who should not be on a GLP-1 at all, is laid out in how we approach weight loss peptides Read nextHow We Approach Weight-Loss PeptidesWeight-loss peptides do a narrower job than a GLP-1: instead of suppressing appetite, they protect lean mass, target visceral fat, and improve how your cells burn fuel. Here is how a provider decides which one fits, and where peptides are oversold.Read article .

Why AOD-9604 Is Still Prescribed

A fair question after all of the above: if the obesity trial failed, why do compounding pharmacies still make AOD-9604, and why do clinics still prescribe it? Three honest reasons. First, the failure was specific: an oral formulation, at low doses, against a demanding endpoint. The injectable form bypasses the digestive tract entirely, and while its efficacy is untested, the pharmacological logic for expecting more from it than from the oral capsules is real. Second, the safety record is genuinely unusual for this space, nearly 900 subjects with no signal, no IGF-1 rise, no glucose disruption. Third, some people specifically want a body composition tool that leaves their hormones and appetite alone, which is a preference no GLP-1 can serve. Prescribing on that basis is defensible as long as nobody pretends the efficacy question is settled. It is not.

There is also a research direction nobody planned. In a 2015 rabbit osteoarthritis model, weekly intra-articular AOD-9604 injections combined with hyaluronic acid improved cartilage preservation more than either alone. That is one animal study and some cell work, not a clinical indication, but it is part of why interest in the fragment never fully died with the obesity program. The regulatory picture, including the GRAS designation and the 503A compounding pathway, is covered in is AOD-9604 FDA approved Read nextIs AOD-9604 FDA Approved? 2026 Legal Status and AccessAOD 9604 completed Phase 2 clinical trials in Australia with 300+ patients. Development paused for efficacy, not safety.Read article , and if you are weighing AOD-9604 against a fat-loss peptide with actual FDA approval behind it, the AOD-9604 vs tesamorelin comparison Read nextAOD-9604 vs Tesamorelin: Fat-Loss PeptidesBoth are used for fat loss and body composition, but they work from opposite ends of the growth-hormone system. AOD-9604 is a small fragment of GH that pushes fat cells to release stored fat without raising your growth hormone or IGF-1. Tesamorelin is an FDA-approved GHRH analog that signals your own pituitary to make more GH, and it carries the strongest visceral-fat trial data in the category. Here is the honest comparison.Read article is the more useful head-to-head. One practical note: AOD-9604 is currently out of stock at PeRx, so the product page Explore PeRxAOD-9604Pure Fat Burning PeptideView peptide is worth checking for status before you get attached to the idea.

Kwon DR, Park GY, "Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model," Annals of Clinical and Laboratory Science, 2015;45(4):426-432. View study

Who Chooses Which

Notice what is absent from the right-hand column: any promise that AOD-9604 will work. That is deliberate. The honest case for it is a preference profile, not an efficacy claim. And if the reason you are avoiding a GLP-1 is fear of losing muscle rather than intolerance, that concern has better answers than a growth hormone fragment: the evidence-ranked options are in peptides to take with a GLP-1 Read nextPeptides to Take With a GLP-1: The EvidenceSearch this question and you get a stack. Every result recommends four or five peptides, none of them ranks the options, and none of them tells you which ones have human data behind them. This page sorts the same list into three tiers and says out loud which tier each one lands in.Read article , and the top of that ranking is protein and resistance training, not a peptide at all.

Compounded Is Not the Same as Approved

One distinction has to survive this whole discussion intact. Ozempic and Wegovy are FDA-approved semaglutide products, manufactured by their sponsor and evaluated by the FDA for safety and effectiveness. PeRx prescribes compounded semaglutide, which is prepared by a licensed 503A compounding pharmacy against an individual prescription and has not been through FDA review. The trial results that made semaglutide famous belong to the approved products. They describe the pharmacology of the molecule, not the regulatory status of a compounded preparation, and a federal court has already allowed a claim to proceed against marketing that blurred exactly that line.

AOD-9604 sits lower on the same ladder. It has never been FDA approved for anything; its GRAS designation covers oral use in foods at up to 1 mg per day and is a food-safety call, not a drug approval. Both products on this page reach patients through the same legal route, a licensed provider writing a prescription filled by a US-based 503A pharmacy, shipped fully reconstituted and ready to use. Same pathway, very different evidence standing behind what is in the vial. Keeping those two things separate is most of what it means to read this market honestly.

Common Questions